Monopar Therapeutics Inc. — Q3 2023 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2023. Monopar is a clinical-stage oncology company with no approved products and no product revenue.
Business context and pipeline
- Camsirubicin: Ongoing Phase 1b dose-escalation trial in advanced soft tissue sarcoma; the company reported 14 patients enrolled and 9 with stable disease to date.
- MNPR-101: Preclinical radiopharmaceutical and imaging program, developed with NorthStar on a 50/50 cost-sharing basis. The company was aiming to begin a first-in-human imaging study with MNPR-101-Zr as early as year-end 2023.
- MNPR-202: Early-stage camsirubicin analog under preclinical evaluation.
- Validive: Phase 2b/3 VOICE trial was discontinued in March 2023 after an interim analysis did not meet the prespecified efficacy threshold.
Financial highlights
| Metric | Q3 2023 | Nine months 2023 | Comparable 2022 period |
|---|---|---|---|
| Revenue | No product revenue | No product revenue | No product revenue |
| Research and development | $1.317 million | $4.565 million | $1.732 million; $5.489 million |
| General and administrative | $0.749 million | $2.355 million | $0.675 million; $2.139 million |
| Total operating expenses | $2.066 million | $6.919 million | $2.407 million; $7.628 million |
| Net loss | $1.954 million | $6.588 million | $2.400 million; $7.619 million |
| Net loss per share, basic and diluted | $0.14 | $0.49 | $0.19; $0.60 |
- At September 30, cash and cash equivalents were $5.515 million, investments were $2.979 million, and total current assets were $8.568 million.
- Total liabilities were $1.982 million, consisting of current liabilities; the balance sheet reported no debt. Stockholders’ equity was $6.611 million.
- Operating cash use for the first nine months was $6.312 million, versus $5.927 million in 2022. Cash and cash equivalents declined $2.671 million; ATM stock sales provided $1.692 million in net financing cash flow.
- The company reported an accumulated deficit of $58.4 million. Interest income increased to $0.112 million for Q3 and $0.331 million for the nine-month period, helping reduce net loss relative to operating loss.
Changes versus prior period
- Q3 operating expenses declined $0.341 million year over year, mainly due to lower Validive-related costs; R&D fell $0.415 million while G&A rose $0.074 million.
- Nine-month operating expenses declined $0.709 million. R&D decreased $0.925 million, partly offset by a $0.216 million increase in G&A. Management attributed lower R&D principally to reduced camsirubicin and Validive expenses, partly offset by increased MNPR-101 preclinical work.
- Nine-month net loss improved by $1.031 million, while operating cash use increased by $0.385 million. The company sold 1,125,479 shares through its ATM program for net proceeds of approximately $1.733 million after fees and expenses.
Outlook, risks and contingencies
- Management estimated available funds would support planned operations at least through November 2024, including the camsirubicin Phase 1b trial and advancement of MNPR-101 toward an initial human imaging study. Management cautioned that higher camsirubicin dose levels could extend the trial and defer topline results beyond mid-2024.
- The company expects to seek additional capital within 12 months. Further development depends on financing and/or collaborations; failure to obtain funding could require delaying, reducing, or terminating programs. Equity financing could dilute shareholders.
- Nasdaq notified the company on August 28, 2023 that it was below the $1.00 minimum bid-price requirement and provided 180 days to regain compliance. The company intended to seek a second 180-day period; delisting could impair its ability to raise funds.
- Management reported no substantial doubt about the company’s ability to continue as a going concern, based on its cash assessment through November 2024. This does not remove the stated need for additional financing to support future development.
- Camsirubicin had shown tumor-dimension reductions in two patients at the fifth dose level, but these are early trial observations. One patient at that dose level had an ongoing decline in left ventricular ejection fraction under assessment for possible cardiotoxicity; no protocol-defined dose-limiting toxicity had been observed to date.
- Other risks include clinical and regulatory uncertainty, patient enrollment and manufacturing dependencies, inflation and geopolitical disruption, competition, and potential limits on use of tax-loss carryforwards. The filing reported no asserted legal claims and no milestones or royalties paid under the cited license agreements.
Investor verification checklist
- Confirm subsequent cash use, financing activity, and whether the stated November 2024 runway remained achievable.
- Check Nasdaq bid-price compliance status and any extension or delisting developments.
- Verify camsirubicin enrollment, dose-escalation progress, cardiac safety findings, and timing of topline results.
- Confirm whether MNPR-101-Zr entered human imaging studies and review any resulting clinical data and collaboration funding needs.
- Track share issuance and remaining ATM capacity, as well as the financial and operational effects of the Validive shutdown.